Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-02-23

AUTHORS

F. Petrelli, S. Barni, Anti-EGFR agents for liver metastases

ABSTRACT

BackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p = 0.0001), the R0 resection rate from 11% to 18% (RR 1.59, p = 0.04) and PFS (HR 0.68, p = 0.002), but not OS (p = 0.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases. More... »

PAGES

997-1004

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2

DOI

http://dx.doi.org/10.1007/s00384-012-1438-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046464035

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22358385


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cetuximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Mutational Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Panitumumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Publication Bias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ras Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417270.7", 
          "name": [
            "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petrelli", 
        "givenName": "F.", 
        "id": "sg:person.0661567716.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661567716.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417270.7", 
          "name": [
            "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barni", 
        "givenName": "S.", 
        "id": "sg:person.0645550356.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645550356.01"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Anti-EGFR agents for liver metastases", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6605259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048476579", 
          "https://doi.org/10.1038/sj.bjc.6605259"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-02-23", 
    "datePublishedReg": "2012-02-23", 
    "description": "BackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p\u2009=\u20090.0001), the R0 resection rate from 11% to 18% (RR 1.59, p\u2009=\u20090.04) and PFS (HR 0.68, p\u2009=\u20090.002), but not OS (p\u2009=\u20090.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00384-012-1438-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096381", 
        "issn": [
          "0179-1958", 
          "1432-1262"
        ], 
        "name": "International Journal of Colorectal Disease", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "metastatic colorectal cancer", 
      "overall response rate", 
      "KRAS wild-type patients", 
      "R0 resection rate", 
      "wild-type patients", 
      "resection rate", 
      "hazard ratio", 
      "relative risk", 
      "KRAS wild-type metastatic colorectal cancer", 
      "liver-limited metastatic colorectal cancer", 
      "response rate", 
      "wild-type metastatic colorectal cancer", 
      "unresectable metastatic colorectal cancer", 
      "unresectable liver-limited disease", 
      "colorectal liver-limited metastases", 
      "liver-limited disease", 
      "liver-limited metastases", 
      "unresectable liver metastases", 
      "Cochrane Central Register", 
      "risk of progression", 
      "anti-EGFR agents", 
      "chemotherapy plus", 
      "ResultsFour RCTs", 
      "radical resection", 
      "Central Register", 
      "overall survival", 
      "liver metastases", 
      "Controlled Trials", 
      "colorectal cancer", 
      "patients", 
      "confidence intervals", 
      "conversion therapy", 
      "RCTs", 
      "survival", 
      "metastasis", 
      "trials", 
      "risk", 
      "ConclusionsThe addition", 
      "BackgroundCetuximab", 
      "resectability", 
      "panitumumab", 
      "resection", 
      "chemotherapy", 
      "EMBASE", 
      "MEDLINE", 
      "PFS", 
      "therapy", 
      "KRAS", 
      "cancer", 
      "MethodsWe", 
      "disease", 
      "progression", 
      "rate", 
      "outcomes", 
      "Register", 
      "OS", 
      "agents", 
      "interval", 
      "addition", 
      "Plus", 
      "effect", 
      "combination", 
      "data", 
      "ratio", 
      "choice", 
      "materials"
    ], 
    "name": "Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis", 
    "pagination": "997-1004", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046464035"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00384-012-1438-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22358385"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00384-012-1438-2", 
      "https://app.dimensions.ai/details/publication/pub.1046464035"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_581.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00384-012-1438-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      21 PREDICATES      110 URIs      101 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00384-012-1438-2 schema:about N00f07b1f7bbb4f4f85d0579f3d1b3b4c
2 N030b30f807184f2baec682a3ac2b21b3
3 N11ab66da2ebc438f95bddf586ce1c55d
4 N2ab8933143d24458bc0983732b389984
5 N37d467a143994326bae39cd0de5d4bbb
6 N3b22d9dd6b9b4a01827b7293340482dc
7 N3e3ce93605c44fac96003a2473bc3756
8 N4b4b9fcb3b0641e8b65291d3e510579e
9 N54a58e331eec49f5aa2a61e602f944d9
10 N8c6447b8fa334688b859cad74e30b20c
11 N8ebbc049ae2d447f8d2f6e77c0c3fa69
12 N9549b330f6b246cc84887b0e04a17b6c
13 Na416769bd44e4ea689c8e640efd2d85c
14 Na6e1af3da15b4602952c35ca44cd4feb
15 Nbdb6385b97484f56a194f5dd0e186404
16 Ncc9776dddc6b40cdacf207d2756573f4
17 Nd6b2d7d884a14d9eb87f56e0f518f168
18 Nfae97a2f56f34ef889473e35419a44b1
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Nb5a32465813249d4b3033580467638b4
22 schema:citation sg:pub.10.1038/sj.bjc.6605259
23 schema:datePublished 2012-02-23
24 schema:datePublishedReg 2012-02-23
25 schema:description BackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p = 0.0001), the R0 resection rate from 11% to 18% (RR 1.59, p = 0.04) and PFS (HR 0.68, p = 0.002), but not OS (p = 0.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N312d76fc7c2d4b54a3d432bd905c2bc7
29 Nc25ff78f5291450db422ff319439e49a
30 sg:journal.1096381
31 schema:keywords BackgroundCetuximab
32 Central Register
33 Cochrane Central Register
34 ConclusionsThe addition
35 Controlled Trials
36 EMBASE
37 KRAS
38 KRAS wild-type metastatic colorectal cancer
39 KRAS wild-type patients
40 MEDLINE
41 MethodsWe
42 OS
43 PFS
44 Plus
45 R0 resection rate
46 RCTs
47 Register
48 ResultsFour RCTs
49 addition
50 agents
51 anti-EGFR agents
52 cancer
53 chemotherapy
54 chemotherapy plus
55 choice
56 colorectal cancer
57 colorectal liver-limited metastases
58 combination
59 confidence intervals
60 conversion therapy
61 data
62 disease
63 effect
64 hazard ratio
65 interval
66 liver metastases
67 liver-limited disease
68 liver-limited metastases
69 liver-limited metastatic colorectal cancer
70 materials
71 metastasis
72 metastatic colorectal cancer
73 outcomes
74 overall response rate
75 overall survival
76 panitumumab
77 patients
78 progression
79 radical resection
80 rate
81 ratio
82 relative risk
83 resectability
84 resection
85 resection rate
86 response rate
87 risk
88 risk of progression
89 survival
90 therapy
91 trials
92 unresectable liver metastases
93 unresectable liver-limited disease
94 unresectable metastatic colorectal cancer
95 wild-type metastatic colorectal cancer
96 wild-type patients
97 schema:name Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis
98 schema:pagination 997-1004
99 schema:productId N5afcc5a2df5e482b99a128a603e7fe02
100 Nb31f0f9472f84a5c899a447ded969350
101 Ned6a52c093544335a84429004e0ae787
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046464035
103 https://doi.org/10.1007/s00384-012-1438-2
104 schema:sdDatePublished 2022-08-04T17:00
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher Ne7047afe0fd841ce9b23527245074b62
107 schema:url https://doi.org/10.1007/s00384-012-1438-2
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N00f07b1f7bbb4f4f85d0579f3d1b3b4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name ErbB Receptors
113 rdf:type schema:DefinedTerm
114 N02c8ade441c24b3c9886c383aacb4a6a rdf:first sg:person.0645550356.01
115 rdf:rest N85ba41ce516f4d988abb0b9907acba13
116 N030b30f807184f2baec682a3ac2b21b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Proto-Oncogene Proteins p21(ras)
118 rdf:type schema:DefinedTerm
119 N11ab66da2ebc438f95bddf586ce1c55d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Humans
121 rdf:type schema:DefinedTerm
122 N2ab8933143d24458bc0983732b389984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Antibodies, Monoclonal
124 rdf:type schema:DefinedTerm
125 N312d76fc7c2d4b54a3d432bd905c2bc7 schema:volumeNumber 27
126 rdf:type schema:PublicationVolume
127 N37d467a143994326bae39cd0de5d4bbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Risk
129 rdf:type schema:DefinedTerm
130 N3b22d9dd6b9b4a01827b7293340482dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name ras Proteins
132 rdf:type schema:DefinedTerm
133 N3e3ce93605c44fac96003a2473bc3756 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Publication Bias
135 rdf:type schema:DefinedTerm
136 N4b4b9fcb3b0641e8b65291d3e510579e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Panitumumab
138 rdf:type schema:DefinedTerm
139 N54a58e331eec49f5aa2a61e602f944d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Proto-Oncogene Proteins
141 rdf:type schema:DefinedTerm
142 N5afcc5a2df5e482b99a128a603e7fe02 schema:name dimensions_id
143 schema:value pub.1046464035
144 rdf:type schema:PropertyValue
145 N85ba41ce516f4d988abb0b9907acba13 rdf:first Nb255ce1f897b4d698435b647ed557485
146 rdf:rest rdf:nil
147 N8c6447b8fa334688b859cad74e30b20c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Cetuximab
149 rdf:type schema:DefinedTerm
150 N8ebbc049ae2d447f8d2f6e77c0c3fa69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Antibodies, Monoclonal, Humanized
152 rdf:type schema:DefinedTerm
153 N9549b330f6b246cc84887b0e04a17b6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Treatment Outcome
155 rdf:type schema:DefinedTerm
156 Na416769bd44e4ea689c8e640efd2d85c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Liver Neoplasms
158 rdf:type schema:DefinedTerm
159 Na6e1af3da15b4602952c35ca44cd4feb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Randomized Controlled Trials as Topic
161 rdf:type schema:DefinedTerm
162 Nb255ce1f897b4d698435b647ed557485 schema:familyName Anti-EGFR agents for liver metastases
163 rdf:type schema:Person
164 Nb31f0f9472f84a5c899a447ded969350 schema:name pubmed_id
165 schema:value 22358385
166 rdf:type schema:PropertyValue
167 Nb5a32465813249d4b3033580467638b4 rdf:first sg:person.0661567716.40
168 rdf:rest N02c8ade441c24b3c9886c383aacb4a6a
169 Nbdb6385b97484f56a194f5dd0e186404 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Colorectal Neoplasms
171 rdf:type schema:DefinedTerm
172 Nc25ff78f5291450db422ff319439e49a schema:issueNumber 8
173 rdf:type schema:PublicationIssue
174 Ncc9776dddc6b40cdacf207d2756573f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Disease-Free Survival
176 rdf:type schema:DefinedTerm
177 Nd6b2d7d884a14d9eb87f56e0f518f168 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Antineoplastic Agents
179 rdf:type schema:DefinedTerm
180 Ne7047afe0fd841ce9b23527245074b62 schema:name Springer Nature - SN SciGraph project
181 rdf:type schema:Organization
182 Ned6a52c093544335a84429004e0ae787 schema:name doi
183 schema:value 10.1007/s00384-012-1438-2
184 rdf:type schema:PropertyValue
185 Nfae97a2f56f34ef889473e35419a44b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name DNA Mutational Analysis
187 rdf:type schema:DefinedTerm
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
192 schema:name Oncology and Carcinogenesis
193 rdf:type schema:DefinedTerm
194 sg:journal.1096381 schema:issn 0179-1958
195 1432-1262
196 schema:name International Journal of Colorectal Disease
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.0645550356.01 schema:affiliation grid-institutes:grid.417270.7
200 schema:familyName Barni
201 schema:givenName S.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645550356.01
203 rdf:type schema:Person
204 sg:person.0661567716.40 schema:affiliation grid-institutes:grid.417270.7
205 schema:familyName Petrelli
206 schema:givenName F.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661567716.40
208 rdf:type schema:Person
209 sg:pub.10.1038/sj.bjc.6605259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048476579
210 https://doi.org/10.1038/sj.bjc.6605259
211 rdf:type schema:CreativeWork
212 grid-institutes:grid.417270.7 schema:alternateName Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
213 schema:name Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...